Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Disclosed deployed
—
across known amounts
Stages
Early stage, Growth Stage, Late stage, Seed, Series A, Series B, Series C
About
SBI JI Innovation Fund was formed in early 2017 as a partnership between SBI Holdings of Japan and Vertex Israel. The fund focuses on bio-investments and is expanding its interests to new sectors and territories, collaborating in Israel and surrounding countries. It cherry-picks Israeli or Israel-related venture-backed biopharma and high-tech companies across different development stages.
Portfolio
No portfolio companies in this dataset yet.
Q&A
- What is the primary focus of SBI JI Innovation Fund?
- SBI JI Innovation Fund is a biopharma-focused venture capital fund that invests in Israeli or Israel-related venture-backed biopharma and high-tech companies.
- When was SBI JI Innovation Fund formed and what is its origin?
- SBI JI Innovation Fund was formed in early 2017 as a partnership between SBI Holdings of Japan and Vertex Israel.
- What investment stages does SBI JI Innovation Fund target?
- SBI JI Innovation Fund targets companies across various development stages, including Seed, Early stage, Series A, Series B, Series C, Growth Stage, and Late stage.
- What are the preferred sectors for investment by SBI JI Innovation Fund?
- The fund's preferred sectors include Healthcare, Life Science, Oncology, Immunology, Biopharmaceutical, Biotechnology, Fintech, Cybersecurity, and High-tech.
- What is the typical check size for investments made by SBI JI Innovation Fund?
- SBI JI Innovation Fund typically invests between $4.7 million and $80 million per company.
- Where is SBI JI Innovation Fund headquartered?
- SBI JI Innovation Fund is headquartered in Tel Aviv-Yafo, Israel.
- Who are the General Partners at SBI JI Innovation Fund?
- David Heller and Ran Gartenberg are General Partners at SBI JI Innovation Fund.
- What is SBI JI Innovation Fund's investment thesis?
- SBI JI Innovation Fund cherry-picks Israeli (or Israel-related) venture-backed biopharma and high-tech companies across different developmental stages, seeking cutting-edge technology, strong management, and scalable roadmaps.